Innovating Works

MLL

Desconocido
GenoMed4ALL: Genomics and Personalized Medicine for all though Artificial Intelligence in Haematological Diseases MLL MUNCHNER LEUKAMIELABOR GMBH participó en un H2020: H2020-SC1-FA-DTS-2018-2020 GENOMED4ALL will support the pooling of genomic, clinical data and other -omics health data (data EHR, PET, MRI and CT , Next Generation Se...
2020-12-04 - 2024-12-31 | Financiado
INTERCEPT-MDS: Exploring cell to cell heterogeneity and exploiting epigenetic regulation for the interception of my... MLL MUNCHNER LEUKAMIELABOR GMBH participó en un H2020: H2020-MSCA-ITN-2020 Disease interception is a novel concept referring to treatment of a disease before the disease fully develops by removing altered cells. To...
2020-08-13 - 2024-12-31 | Financiado
HARMONY PLUS: HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY PLUS MLL MUNCHNER LEUKAMIELABOR GMBH participó en un H2020: H2020-JTI-IMI2-2019-19-single-stage Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be e...
2020-05-26 - 2024-03-31 | Financiado
HARMONY: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY Sofia ref.... MLL MUNCHNER LEUKAMIELABOR GMBH participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in qual...
2016-12-22 - 2023-06-30 | Financiado
NGS-PTL: Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia MLL MUNCHNER LEUKAMIELABOR GMBH participó en un FP7: Hematological diseases are highly heterogeneous malignancies in the matter of the molecular mechanisms related to their development and prog...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.